Loading...
•
Jun 30, 2024
Bicycle Q2 2024 Earnings Report
Reported business progress and financial results.
Key Takeaways
Bicycle Therapeutics reported progress in its pipeline, highlighting the profiles of Bicycle Toxin Conjugates, and strengthened its balance sheet with $555 million from a private investment. The company's cash and cash equivalents were $961.4 million as of June 30, 2024, expected to provide financial runway into 2H 2027.
Four abstracts containing data updates across clinical pipeline accepted for poster presentation at ESMO Congress 2024
Focused R&D pipeline on clinical programs and research areas that have the highest potential to maximize value creation
Streamlined leadership team to better align with strategic and pipeline priorities, and enhanced oncology expertise with formation of Clinical Advisory Board
Strengthened balance sheet with gross proceeds of approximately $555 million from May 2024 private investment in public equity (PIPE) financing
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...